Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Cash & Equivalents: 2018-2025

  • China SXT Pharmaceuticals' Cash & Equivalents rose 50.11% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.1 million, marking a year-over-year increase of 50.11%. This contributed to the annual value of $18.1 million for FY2025, which is 49.95% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Cash & Equivalents stood at $18.1 million for Q3 2025, which was up 0.17% from $18.1 million recorded in Q1 2025.
  • China SXT Pharmaceuticals' 5-year Cash & Equivalents high stood at $18.1 million for Q3 2025, and its period low was $12.1 million during Q1 2024.
  • Over the past 3 years, China SXT Pharmaceuticals' median Cash & Equivalents value was $17.4 million (recorded in 2023), while the average stood at $15.9 million.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Cash & Equivalents spiked by 83.33% in 2021, and later tumbled by 30.50% in 2024.
  • Quarterly analysis of 5 years shows China SXT Pharmaceuticals' Cash & Equivalents stood at $13.4 million in 2021, then climbed by 16.55% to $15.6 million in 2022, then climbed by 11.55% to $17.4 million in 2023, then plummeted by 30.46% to $12.1 million in 2024, then spiked by 50.11% to $18.1 million in 2025.
  • Its last three reported values are $18.1 million in Q3 2025, $18.1 million for Q1 2025, and $12.1 million during Q3 2024.